Research and development
We have an expertise in developing medicines for patients treated by specialist physicians, and for discovering new therapies for rare, life-threatening genetic disease. Shire’s two divisions take distinct approaches to R&D. 
In Specialty Pharmaceuticals, we use a more traditional model of taking a project through the pre-clinical and clinical trials phases. We look to acquire projects in later stages of development, offering lower risk for Shire and our investors, and offering increased possibility of getting medicines to market more quickly.
Our Human Genetic Therapies division has leading-edge expertise in enzyme replacement therapy and a focus on developing treatments for other rare diseases. This has allowed us to develop a number of effective treatments for conditions caused by enzyme or protein deficiencies. The human cell line technology platform is unique to Shire.
Key fact
We try to find new therapies
for rare and life-threatening
diseases.
